Effect of Passive Immunization with Serotype-Specific Monoclonal Antibodies on Actinobacillus pleuropneumoniae Infection of Mice.

Saze, Koh-ichi; Kinoshita, Chikako; Shiba, F.; Haga, Yoshihisa; Sudo, Tomoko; Hashimoto, Kazunori

doi:10.1292/jvms.56.97

Cited by 5 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pigs and mice immunized with LPS were previously found to be partially protected upon homologous challenge with A. pleuropneumoniae serotype 1 (Rioux et al, 1997(Rioux et al, , 1998 while cross-serotype challenge experiments in mice vaccinated with LPS showed no protection (Rioux et al, 1997). Passive immunization of mice with monoclonal antibodies directed against LPS also failed to provide protection against the heterologous serotype of A. pleuropneumoniae (Saze et al, 1994). Moreover, pigs immunized with purified LPS or capsule were not protected against challenge with the homologous A. pleuropneumoniae serotype 5 (Inzana et al, 1988), and other studies also showed that neither the capsule nor the LPS seemed to be directly correlated with protection of mice in A. pleuropneumoniae challenge experiments (Byrd and Hooke, 1997).…”

Section: Virulence Factors Of a Pleuropneumoniae And Subunit Vaccinementioning

confidence: 99%

Actinobacillus pleuropneumoniaevaccines: from bacterins to new insights into vaccination strategies

Ramjeet

Deslandes

Gouré

et al. 2008

Anim. Health. Res. Rev.

111

View full text Add to dashboard Cite

With the growing emergence of antibiotic resistance and rising consumer demands concerning food safety, vaccination to prevent bacterial infections is of increasing relevance. Actinobacillus pleuropneumoniae is the etiological agent of porcine pleuropneumonia, a respiratory disease leading to severe economic losses in the swine industry. Despite all the research and trials that were performed with A. pleuropneumoniae vaccination in the past, a safe vaccine that offers complete protection against all serotypes has yet not reached the market. However, recent advances made in the identification of new potential vaccine candidates and in the targeting of specific immune responses, give encouraging vaccination perspectives. Here, we review past and current knowledge on A. pleuropneumoniae vaccines as well as the newly available genomic tools and vaccination strategies that could be useful in the design of an efficient vaccine against A. pleuropneumoniae infection.

show abstract

Section: Virulence Factors Of a Pleuropneumoniae And Subunit Vaccinementioning

confidence: 99%

Actinobacillus pleuropneumoniaevaccines: from bacterins to new insights into vaccination strategies

Ramjeet

Deslandes

Gouré

et al. 2008

Anim. Health. Res. Rev.

111

View full text Add to dashboard Cite

show abstract

“…Hybrid cells were selected in HAT medium, and the hybridomas producing antibodies specific for hemolysin(s) were screened by enzyme-linked immunosorbent assay (ELISA). The ELISA procedure was essentially the same as previously described [20], except that hemolysin preparation was used as a immobilized antigen. ELISA-positive hybridomas were cloned by limiting dilution technique.…”

mentioning

confidence: 99%

Protective Efficacy of an Affinity-Purified Hemolysin Vaccine against Experimental Swine Pleuropneumonia.

Haga

Ogino

Ohashi

et al. 1997

The Journal of Veterinary Medical Science

Self Cite

View full text Add to dashboard Cite

ABSTRACT. Protective efficacy of Actinobacillus pleuropneumoniae extracellular hemolytic toxins, RTX-toxin I (Apx I) and Apx II, was evaluated in pigs. The hemolysins were purified from culture supernatant of A. pleuropneumoniae strain HA-337, serotype 1 by immunoaffinity chromatography using a monoclonal antibody specific for Apx I or Apx II as ligand. Four pigs were vaccinated with the purified hemolysins adsorbed on aluminium phosphate gel adjuvant. Four pigs of a control group were given placebo. Hemolysinneutralizing antibodies were detected only in vaccinated group after booster injection. One of four control pigs died following an aerosol challenge with the homologous strain, and three surviving pigs developed serious clinical signs of pneumonia and had extensive lung lesions. In contrast, there was no mortality in vaccinated group. Only transient hyperthermia was observed in two vaccinated pigs after challenge. At necropsy, two vaccinated pigs had slight localized pulmonary lesions, though the remaining two had no lung lesions at all. These results indicate that the hemolysin vaccine made of Apx I and Apx II has good protective activity against swine pleuropneumonia caused by A. pleuropneumoniae serotype 1. -KEY WORDS: Actinobacillus pleuropneumoniae, Apx, immunoaffinity chromatography, vaccine.

show abstract

“…Several previous studies have shown that mice or pigs actively immunized with toxins or passively immunized with ApxI‐specific antibodies are protected against challenge with homologous serovar strains . The role of antibodies to CPS and LPS in protection has also been reported by other investigators . Interestingly, Oishi et al .…”

Section: Discussionmentioning

confidence: 59%

Genetic and antigenic characteristics of ApxIIA and ApxIIIA fromActinobacillus pleuropneumoniaeserovars 2, 3, 4, 6, 8 and 15

Nagai

Iwata

et al. 2016

Microbiology and Immunology

View full text Add to dashboard Cite

Apx toxins produced by Actinobacillus pleuropneumoniae are essential components of new generation vaccines. In this study, apxIIA and apxIIIA genes of serovars 2, 3, 4, 6, 8 and 15 were cloned and sequenced. Amino acid sequences of ApxIIA proteins of serovars 2, 3, 4, 6, 8 and 15 were almost identical to those of serovars 1, 5, 7, 9 and 11-13. Immunoblot analysis showed that rApxIIA from serovars 2 and 15 reacts strongly with sera from animals infected with various serovars. Sequence analysis revealed that ApxIIIA proteins has two variants, one in strains of serovar 2 and the other in strains of serovars 3, 4, 6, 8 and 15. A mouse cross-protection study showed that mice actively immunized with rApxIIIA/2 or rApxIIIA/15 are protected against challenge with A. pleuropneumoniae strains of serovars 3, 4, 6, 8, 15, and 2 expressing ApxIII/15 and ApxIII/2, respectively. Similarly, mice passively immunized with rabbit anti-rApxIIIA/2 or anti-rApxIIIA/15 sera were found to be protected against challenge with strains of serovars 2 and 15. Our study revealed antigenic and sequence similarities within ApxIIA and ApxIIIA proteins, which may help in the development of effective vaccines against disease caused by A. pleuropneumoniae.

show abstract

Effect of Passive Immunization with Serotype-Specific Monoclonal Antibodies on Actinobacillus pleuropneumoniae Infection of Mice.

Cited by 5 publications

References 19 publications

Actinobacillus pleuropneumoniaevaccines: from bacterins to new insights into vaccination strategies

Actinobacillus pleuropneumoniaevaccines: from bacterins to new insights into vaccination strategies

Protective Efficacy of an Affinity-Purified Hemolysin Vaccine against Experimental Swine Pleuropneumonia.

Genetic and antigenic characteristics of ApxIIA and ApxIIIA fromActinobacillus pleuropneumoniaeserovars 2, 3, 4, 6, 8 and 15

Contact Info

Product

Resources

About